Dynavax Technologies
Clinical trials sponsored by Dynavax Technologies, explained in plain language.
Dynavax Technologies
DVAX
NASDAQ
A biopharmaceutical company developing vaccines and immunotherapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New plague vaccine enters human testing Results expected Jan 2027 (estimated)